China
· Delayed Price · Currency is CNY Gan & Lee Pharmaceuticals. Statistics
Total Valuation
Gan & Lee Pharmaceuticals. has a market cap or net worth of CNY 23.59 billion. The enterprise value is 18.73 billion.
| Market Cap | 23.59B |
| Enterprise Value | 18.73B |
Important Dates
The next estimated earnings date is Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | Jun 18, 2024 |
Share Statistics
Gan & Lee Pharmaceuticals. has 597.09 million shares outstanding. The number of shares has increased by 3.51% in one year.
| Shares Outstanding | 597.09M |
| Shares Change (YoY) | +3.51% |
| Shares Change (QoQ) | -4.65% |
| Owned by Insiders (%) | 36.55% |
| Owned by Institutions (%) | 8.14% |
| Float | 294.54M |
Valuation Ratios
The trailing PE ratio is 45.42 and the forward PE ratio is 27.63.
| PE Ratio | 45.42 |
| Forward PE | 27.63 |
| PS Ratio | 8.51 |
| PB Ratio | 2.06 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 41.95, with an EV/FCF ratio of -60.55.
| EV / Earnings | 37.10 |
| EV / Sales | 6.95 |
| EV / EBITDA | 41.95 |
| EV / EBIT | 90.02 |
| EV / FCF | -60.55 |
Financial Position
The company has a current ratio of 8.29, with a Debt / Equity ratio of 0.06.
| Current Ratio | 8.29 |
| Quick Ratio | 6.89 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | -0.02 |
| Interest Coverage | 761.08 |
Financial Efficiency
Return on equity (ROE) is 4.87% and return on invested capital (ROIC) is 1.25%.
| Return on Equity (ROE) | 4.87% |
| Return on Assets (ROA) | 1.15% |
| Return on Capital (ROIC) | 1.25% |
| Revenue Per Employee | 600,885 |
| Profits Per Employee | 112,632 |
| Employee Count | 4,482 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 0.88 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -0.48% in the last 52 weeks. The beta is 1.58, so Gan & Lee Pharmaceuticals.'s price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | -0.48% |
| 50-Day Moving Average | 42.87 |
| 200-Day Moving Average | 45.69 |
| Relative Strength Index (RSI) | 38.30 |
| Average Volume (20 Days) | 4,577,762 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Gan & Lee Pharmaceuticals. had revenue of CNY 2.69 billion and earned 504.82 million in profits. Earnings per share was 0.87.
| Revenue | 2.69B |
| Gross Profit | 1.95B |
| Operating Income | 208.04M |
| Pretax Income | 487.30M |
| Net Income | 504.82M |
| EBITDA | 440.16M |
| EBIT | 208.04M |
| Earnings Per Share (EPS) | 0.87 |
Balance Sheet
The company has 4.87 billion in cash and 6.15 million in debt, giving a net cash position of 4.86 billion or 8.14 per share.
| Cash & Cash Equivalents | 4.87B |
| Total Debt | 6.15M |
| Net Cash | 4.86B |
| Net Cash Per Share | 8.14 |
| Equity (Book Value) | 10.98B |
| Book Value Per Share | 19.19 |
| Working Capital | 5.57B |
Cash Flow
In the last 12 months, operating cash flow was 233.85 million and capital expenditures -543.17 million, giving a free cash flow of -309.32 million.
| Operating Cash Flow | 233.85M |
| Capital Expenditures | -543.17M |
| Free Cash Flow | -309.32M |
| FCF Per Share | -0.52 |
Margins
Gross margin is 72.27%, with operating and profit margins of 7.72% and 18.74%.
| Gross Margin | 72.27% |
| Operating Margin | 7.72% |
| Pretax Margin | 18.09% |
| Profit Margin | 18.74% |
| EBITDA Margin | 16.34% |
| EBIT Margin | 7.72% |
| FCF Margin | -11.49% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 0.51%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 0.51% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 20.09% |
| Buyback Yield | -3.51% |
| Shareholder Yield | -3.00% |
| Earnings Yield | 2.20% |
| FCF Yield | -1.31% |
Stock Splits
The last stock split was on August 20, 2020. It was a forward split with a ratio of 1.4.
| Last Split Date | Aug 20, 2020 |
| Split Type | Forward |
| Split Ratio | 1.4 |